Companies Cryptocurrencies
Uniqure NV
Uniqure NV
Exchange: Nasdaq Global Select
IPO Date: 05/02/2014
CEO: Mr. Matthew Craig Kapusta
Biotechnology Healthcare đź”—
  • QURE
  • 33.1
  • 1526528896
    market cap
  • -0.20000076
If you bought

shares of Uniqure NV (QURE) on
You would have made
Old Price $12 Current Price $12

uniQure NV engages in the research, development, and commercialization of gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 212 full-time employees. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Address: Paasheuvelweg 25a AMSTERDAM NOORD-HOLLAND 1105 BP

Stay updated.